This webinar will specifically highlight high-throughput, affinity-based screening with DNA-encoded libraries, elucidation of weak or reversible small molecule–protein interactions with covalent labeling, and targeted protein degradation with bifunctional degraders. Together, these tools are accelerating the identification and development of molecules that bind and functionally alter undruggable proteins.
Who Should Attend?
- Academic researchers
- Pharma researchers
- Drug discovery scientists
Speakers
John Fetter Ph.D
MilliporeSigma
Product Manager, Emerging Chemical Synthesis
John received his Ph.D. in biochemistry from Michigan State University where he studied cytochrome c oxidase with Shelagh Ferguson-Miller. Then he worked in drug discovery research at North Carolina State, SmithKline Beecham, and Taxolog. After that, he moved to Sigma-Aldrich, now known as MilliporeSigma, where he worked on developing assays for pharmaceutical screening. He is currently a product manager in the emerging chemical synthesis where he develops products that use chemical synthesis for life science applications. Much of his focus has been on developing a portfolio of bioconjugation products. He has recently been working on making DNA-encoded libraries more accessible through their availability as off-the-shelf kits.
Angelo Lanzilotto
MilliporeSigma
Technology Manager Chemistry Innovation
Angelo Lanzilotto obtained his PhD in Chemistry from the University of Basel in 2017 and has since then worked in therapeutic discovery of biologics and medicinal chemistry. He joined MilliporeSigma in 2021 as a Scientific Specialist for Chemistry and later moved to the Technology Management team, where he focuses on the introduction of new products, from reagents to instrumentation, including software and services.
Chemistry and synthesis
- Protein degradation
Duration:1h
Language:English
To continue reading please sign in or create an account.
Don't Have An Account?